



Patients name

Address

Phone no.

E-mail

DOB

NHI

ACC

Insurance

Yes

No

Provider

**Referring Practitioner**

Name

NZNM provider #

Phone no.

Date

Please send all therapy related correspondence to:

Signature

**Diagnosis**

**NET Primary Site:**

Pancreas

Small intestine

Other

Ki67 (highest sample)

ECOG Performance status

Functional tumour:

Yes

No

Family history:

Yes

No

Chromogranin A

Date

24 hr Urine 5HIAA

Date

Other tumour marker

Date

**Current tumour related symptoms:**

Diarrhoea

Yes

No

Frequency

Flushing

Yes

No

Frequency

Other

**Reason for Referral:**

Radiological progression

Biochemical progression

Uncontrolled symptoms

Other

(despite medical management)

Allergies

Other medical history

Current medications and dosages

Octreotide injection dose and interval

Dose

Date of last octreotide LAR

Latest imaging

Gatate PET-CT Date

FDG PET-CT Date

Other imaging  Yes  No

Details

### Kindly attach:

- Recent Blood Results (FBC, U&E, LFT, Chromogranin A, 5HIAA, other tumour markers)
- Most recent clinical letter (past and current medical history)
- Most recent echocardiogram report (where available)

### Eligibility criteria for PRRT Therapy

PRRT will be administered following assessment of suitability by a Nuclear Medicine Specialist and managed in close collaboration with the patient's medical oncologist. The following criteria should be met in order to be suitable for PRRT.

### Inclusion criteria

1. PRRT recommended by the National NET MDM
2. Inoperable locally advanced or unresectable metastatic NET
3. Significant tumour SSTR expression on PET-CT (Krenning score 3-4, i.e. >liver uptake)
4. No evidence of macroscopic, SSRT-negative, areas of discordant FDG avid disease
5. Pheochromocytoma / paraganglioma / neuroblastoma: has failed or unsuitable for I-131 MIBG
6. If previously treated with PRRT: evidence of therapeutic benefit (symptoms or oncologic control)
7. No evidence of clinically significant carcinoid heart disease (symptomatic right heart failure, moderate – severe tricuspid / pulmonary regurgitation stenosis)
8. ECOG performance status > 2
9. Expected survival > 6 months
10. Adequate haematological, renal and hepatic functions as defined by:
  - Platelet count > 50 x 1009 /L
  - Haemoglobin ≥ 80 g/L (transfusion permissible)
  - Albumin ≥ 25 g/L (unless long-standing owing to chronic condition)
  - eGFR ≥ 40ml/min